# A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05652894/  
OnCo record `nct05652894` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pucotenlimab, run by Taizhou Hanzhong biomedical co. LTD in colorectal cancer, active.

## Summary

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05652894 by Taizhou Hanzhong biomedical co. LTD, with 190 participants planned, started 2023-02-28. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05652894
- Phase: 3
- Setting: A Randomized Phase III Study of HX008 (a Humanized Monoclonal Antibody Against PD-1) Compared to Investigator's Choice Chemotherapy in the First-Line Treatment of Subjects With Microsatellite Instability-High (MSI-H)/Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
- Sponsor: Taizhou Hanzhong biomedical co. LTD
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT05652894: https://clinicaltrials.gov/study/NCT05652894

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)

---
JSON: https://onco.cc/api/v1/entities/nct05652894.json